Skip to content
SEARCH
Investing
Tech
Application Software
Communications
Computer Hardware
Online Media
Semiconductors
Consumer
Autos
Beverages
Consumer Packaged Goods
Entertainment
Manufacturing
Restaurants
Retail
Travel & Leisure
Financial
Asset Management
Banks
Brokers & Exchanges
Credit Services
Insurance
Politics
Trump
US Budget
Health
Healthcare
Biotechnology
Drug Manufacturers
Pharmaceutical
Basic Materials
Agriculture
Metals & Mining
Cobalt
Zinc
Gold
Silver
Lithium
Uranium
Copper
Energy
Oil & Gas
Alternative Energy
Biofuels
Hydro
Solar
Industrials
Aerospace and Defense
Airlines
Business Services
Consulting and Outsourcing
Farm & Construction Machinery
Industrial Products
Transportation & Logistics
Search
SEARCH FOR AN ARTICLE
Search
Search
Investing
Tech
Application Software
Communications
Computer Hardware
Online Media
Semiconductors
Consumer
Autos
Beverages
Consumer Packaged Goods
Entertainment
Manufacturing
Restaurants
Retail
Travel & Leisure
Financial
Asset Management
Banks
Brokers & Exchanges
Credit Services
Insurance
Politics
Trump
US Budget
Health
Healthcare
Biotechnology
Drug Manufacturers
Pharmaceutical
Basic Materials
Agriculture
Metals & Mining
Cobalt
Zinc
Gold
Silver
Lithium
Uranium
Copper
Energy
Oil & Gas
Alternative Energy
Biofuels
Hydro
Solar
Industrials
Aerospace and Defense
Airlines
Business Services
Consulting and Outsourcing
Farm & Construction Machinery
Industrial Products
Transportation & Logistics
SEARCH
Home
Vascepa
Vascepa
Biotechnology
AMRN Stock Jumps 5% After FDA Approves Vascepa for Wider Use
December 16, 2019
Biotechnology
AMRN Stock Extends Rally as FDA Approves Vascepa Label Expansion
November 15, 2019
LATEST NEWS
Investing News
Wall Street’s Best Week of 2024: Stock Market Weekly Gains
Investing News
Rivian Stock: Buy Now or Take a Wait-and-See Approach?
Investing News
Visa Stock Analysis: Is V a Strong Buy for 2025?
Investing News
Intel Stock Recovery: Challenges and Future Outlook
Investing News
Microsoft Stock Analysis: Buy, Sell, or Hold?